Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schönberg disease (type II autosomal dominant osteopetrosis)

Clinical Chemistry

Volumn 50, Issue 5, 2004, Pages 883-890

  Alatalo, Sari L ^a   Ivaska, Kaisa K ^a   Waguespack, Steven G ^b   Econs, Michael J ^c   Väänänen, H Kalervo ^a   Halleen, Jussi M ^a,d  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d Pharmatest Services Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ISOENZYME; OSTEOCALCIN; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALBERS SCHOENBERG DISEASE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FRACTURE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOCLAST; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ACID PHOSPHATASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHLORIDE CHANNELS; FEMALE; FRACTURES, BONE; HETEROZYGOTE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPETROSIS;

EID: 2142810972     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.029355     Document Type: Article

References (34)

1. Albers-Schönberg HE. Röntgenbilder einer seltenen Knochenerkrankung. Munch Med Wochenschr 1904;51:365.
2. Benichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albers-Schönberg disease): clinical and radiological manifestations in 42 patients. Bone 2000;26:87-93.
3. Bollerslev J. Osteopetrosis. A genetic and epidemiological study. Clin Genet 1987;31:86-90.
4. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, et al. Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001;104:205-15.
5. Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, et al. Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 1993;14:865-9.
6. Benichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul MC, Van Hul W. Mapping of autosomal dominant osteopetrosis type II (Albers-Schönberg disease) to chromosome 16p13.3. Am J Hum Genet 2001;69:647-54.
7. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, et al. Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001;10:2861-7.
8. Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 2003;18:1513-8.
9. Hinkel CL, Beiler DD. Osteopetrosis in adults. Am J Roentgenol Radium Ther Nucl Med 1955;74:46-64.
10. Johnston CC Jr, Lavy N, Lord T, Vellios F, Merritt AD, Deiss WP Jr. Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine (Balt) 1968;47:149-67.
11. Bollerslev J, Andersen PE Jr. Fracture patterns in two types of autosomal-dominant osteopetrosis. Acta Orthop Scand 1989;60: 110-2.
12. el-Tawil T, Stoker DJ. Benign osteopetrosis: a review of 42 cases showing two different patterns. Skeletal Radiol 1993;22:587-93.
13. Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V. Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. Hum Genet 2003;112: 186-9.
14. Milgram JW, Jasty M. Osteopetrosis. A morphological study of twenty-one cases. J Bone Joint Surg Am 1982;64:912-29.
15. Teti A, Migliaccio S, Taranta A, Bernardini S, De Rossi G, Luciani M, et al. Mechanisms of osteoclast dysfunction in human osteopetrosis: abnormal osteoclastogenesis and lack of osteoclast-specific adhesion structures. J Bone Miner Res 1999:14:2107-17.
16. Semba I, Ishigami T, Sugihara K, Kitano M. Higher osteoclastic demineralization and highly mineralized cement lines with osteocalcin deposition in a mandibular cortical bone of autosomal dominant osteopetrosis type II: ultrastructural and undecalcified histological investigations. Bone 2000;27:389-95.
17. Bollerslev J, Ueland T, Landaas S, Marks SC Jr. Serum creatine kinase isoenzyme BB in mammalian osteopetrosis. Clin Orthop 2000;377:241-7.
18. Waguespack SG, Hui SL, White KE, Buckwalter KA, Econs MJ. Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab 2002;87:2212-7.
19. Bollerslev J, Andersen PE Jr. Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. Bone 1988;9:7-13.
20. Bollerslev J, Ueland T, Grodum E, Haug E, Brixen K, Djoseland O. Biochemical markers of bone metabolism in benign human osteopetrosis: a study of two types at baseline and during stimulation with triiodothyronine. Eur J Endocrinol 1998;139:29-35.
21. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 2002;320:49-58.
22. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15: 1337-45.
23. Käkönen SM, Hellman J, Karp M, Laaksonen P, Obrant KJ, Väänänen HK, et al. Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum. Clin Chem 2000;46:332-7.
24. Lam WK, Eastlund DT, Li CY, Yam LT. Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 1978;24:1105-8.
25. Hayman AR, Jones SJ, Boyde A, Foster D, Colledge WH, Carlton MB, et al. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 1996;122:3151-62.
26. Angel NZ, Walsh N, Forwood MR, Ostrowski MC, Cassady AI, Hume DA. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res 2000;15:103-10.
27. Väänänen HK, Zhao H. Osteoclast function. Biology and mechanisms. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology, 2nd ed. San Diego: Academic Press, 2002:127-39.
28. Halleen JM, Räisänen S, Salo JJ, Reddy SV, Roodman GD, Hentunen TA, et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999;274: 22907-10.
29. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001;47:597-600.
30. Alatalo SL, Ivaska KK, Cheng S, Schmidt-Gayk H, Uusi-Rasi K, Nenonen A, et al. Comparison of serum tartrate-resistant acid phosphatase 5b with other markers of bone turnover in monitoring alendronate therapy [Abstract]. J Bone Miner Res 2002;17:S316.
31. Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003;41:1052-9.
32. Alatalo SL, Halleen JM, Hentunen TA, Mönkkönen J, Väänänen HK. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant add phosphatase 5b activity secreted into the culture medium. Clin Chem 2000;46:1751-4.
33. Bollerslev J, Thomas S, Grodum E, Brixen K, Djoseland O. Collagen metabolism in two types of autosomal dominant osteopetrosis during stimulation with thyroid hormones. Eur J Endocrinol 1995;133:557-63.
34. Bollerslev J, Nielsen HK, Larsen HF, Mosekilde L. Biochemical evidence of disturbed bone metabolism and calcium homeostasis in two types of autosomal dominant osteopetrosis. Acta Med Scand 1988;224:479-83.